On Tuesday, Emergent ($NYSE:EBS) BioSolutions, a global life sciences company that focuses on developing and manufacturing treatments for infectious diseases, announced that 400 jobs would be eliminated as part of its 2023 Layoff Tracker. Emergent BioSolutions is a publicly traded company on the New York Stock Exchange and has a long history of providing innovative solutions for public health emergencies. This includes the production of NARCAN, a nasal spray approved by the U.S. Food and Drug Administration (FDA) to counter opioid overdoses. The 400 job cuts are a part of a larger restructuring plan that also includes facility closures, factory optimization, and other cost-cutting measures.
The plan is expected to result in annual savings of $30 million for the company. While the job losses are unfortunate, Emergent BioSolutions believes that these drastic measures are necessary to ensure the long-term sustainability of the business.
On Tuesday, Emergent BioSolutions announced that it will be cutting 400 jobs by 2023 in order to reduce costs and restructure its operations. This decision comes as the company seeks to improve its financial performance by streamlining operations and cutting expenses. As a result of this restructuring, Emergent BioSolutions will be able to focus more resources on certain areas which will help the company in the long run. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Emergent Biosolutions. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Emergent Biosolutions. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Emergent Biosolutions. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Emergent Biosolutions are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
Analysis – Emergent Biosolutions Intrinsic Value
At GoodWhale, we have been closely monitoring EMERGENT BIOSOLUTIONS‘s financials and analysis. Our proprietary Valuation Line indicates that the fair value of EMERGENT BIOSOLUTIONS share is around $30.4. Currently, EMERGENT BIOSOLUTIONS stock is traded at $7.2, which is undervalued by a whopping 76.3%. Thus, if you are looking for a good investment opportunity, EMERGENT BIOSOLUTIONS is a great option. More…
Risk Rating Analysis
Star Chart Analysis
The competition in the global market for biopharmaceuticals is intense. The leading companies are all vying for market share with innovative products and cutting-edge research and development. Emergent BioSolutions Inc is one of the leading companies in this industry, and its main competitors are Phoenix Life Sciences International Ltd, Swedencare AB, Avivagen Inc.
– Phoenix Life Sciences International Ltd ($OTCPK:PLSI)
At 365.91k, Phoenix Life Sciences International Ltd has a market cap that is significantly lower than many of its competitors. However, its Return on Equity of -23.05% is much higher than many of its peers. This indicates that the company is doing a better job of generating profits for its shareholders.
Phoenix Life Sciences International Ltd is a pharmaceutical company that focuses on the development and commercialization of innovative drugs and therapies. The company has a strong portfolio of products in various stages of development, including several that are already on the market. Phoenix Life Sciences International Ltd is a relatively small company, but it has a strong potential for growth.
Swedencare AB is a pharmaceutical company that focuses on developing and commercializing products for the treatment of animals. The company has a market cap of 574.34M as of 2022 and a ROE of 0.81%. Swedencare’s products are available in over 50 countries and are used by veterinarians and pet owners alike. The company’s mission is to improve the quality of life for animals by providing innovative and effective solutions to common health problems.
Avivagen Inc is a Canadian biotechnology company that is engaged in the research, development and commercialization of natural products for the animal health industry. The company’s products are based on its proprietary technology, which leverages the natural properties of oxygen to kill bacteria and viruses. Avivagen’s products are designed to improve the health and productivity of livestock animals, companion animals and fish.
Avivagen Inc has a market cap of 10.42M as of 2022, a Return on Equity of 64.42%. The company’s products are based on its proprietary technology, which leverages the natural properties of oxygen to kill bacteria and viruses. Avivagen’s products are designed to improve the health and productivity of livestock animals, companion animals and fish.
Emergent BioSolutions is facing a difficult period, as the company recently announced 400 job cuts. This has caused some uncertainty about the company’s future, but it could present an interesting investing opportunity. EMERGENT BIOSOLUTIONS is a biopharmaceutical company that produces a wide range of products, from vaccines to treatments for infectious diseases and opioid addiction. Analysts are encouraged by the company’s strong pipeline of products and its products’ ability to rapidly capture market share. The company’s financials are solid, with good cash flow and a balance sheet that reflects strong growth.
However, investors should consider the potential risks associated with the job cuts and the uncertainty surrounding their impact on the company’s business strategy.